FR2848853A1 - Treatment of post-menopausal syndrome, using pharmaceutical or dietetic compositions containing synergistic combination of soya isoflavones, soya saponins and vitamin K - Google Patents
Treatment of post-menopausal syndrome, using pharmaceutical or dietetic compositions containing synergistic combination of soya isoflavones, soya saponins and vitamin K Download PDFInfo
- Publication number
- FR2848853A1 FR2848853A1 FR0304213A FR0304213A FR2848853A1 FR 2848853 A1 FR2848853 A1 FR 2848853A1 FR 0304213 A FR0304213 A FR 0304213A FR 0304213 A FR0304213 A FR 0304213A FR 2848853 A1 FR2848853 A1 FR 2848853A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- soya
- saponins
- isoflavones
- post
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 229930003448 Vitamin K Natural products 0.000 title claims abstract description 11
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 235000019168 vitamin K Nutrition 0.000 title claims abstract description 11
- 239000011712 vitamin K Substances 0.000 title claims abstract description 11
- 150000003721 vitamin K derivatives Chemical class 0.000 title claims abstract description 11
- 229940046010 vitamin k Drugs 0.000 title claims abstract description 11
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 9
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 150000002515 isoflavone derivatives Chemical class 0.000 title claims abstract description 7
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 7
- 235000005911 diet Nutrition 0.000 title claims abstract description 6
- 230000000378 dietary effect Effects 0.000 title claims abstract description 5
- 235000010469 Glycine max Nutrition 0.000 title abstract 2
- 244000068988 Glycine max Species 0.000 title abstract 2
- 229930187719 Soyasaponin Natural products 0.000 title abstract 2
- 239000011885 synergistic combination Substances 0.000 title 1
- 239000002417 nutraceutical Substances 0.000 claims abstract description 4
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 4
- 235000016709 nutrition Nutrition 0.000 claims abstract description 4
- 235000003687 soy isoflavones Nutrition 0.000 claims description 8
- 229930188627 soysaponin Natural products 0.000 claims description 7
- 229930182490 saponin Natural products 0.000 claims description 5
- 235000017709 saponins Nutrition 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940068088 vitamin k 1 Drugs 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 206010060800 Hot flush Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Abstract
Description
ii
La présente invention concerne des compositions pharmaceutiques, nutraceutiques, diététiques, nutritionnelles pour le traitement du syndrome postménopausique, contenant: a) des saponines de soja; b) des isoflavones de soja; c) de la vitamine K. Le syndrome post-ménopausique, caractérisé par des bouffées de chaleur, transpiration, céphalée, nervosisme, dépression, et ostéoporose, est depuis longtemps traité avec la thérapie hormonale substitutive avec des 10 oestrogènes, dont les risques sont cependant bien connus En effet l'administration d'oestrogènes, surtout pendant une longue période, peut favoriser l'apparition de tumeurs provoquées par ceux-ci Une alternative à la thérapie substitutive avec des oestrogènes est celle qui utilise des isoflavones de soja, dont I 'activité similaire à celle des oestrogènes est abondamment 15 documentée par la littérature Cette activité similaire à celle des oestrogènes se révèle extrêmement utile dans le traitement du syndrome post-ménopausique, car non seulement elle provoque une réduction des symptômes comme les bouffées de chaleur, nervosisme, maux de tête, palpitations, mais elle permet aussi de lutter contre les problèmes liés à l'ostéoporose, grâce à son action 20 inhibitrice sur la tyrosine kinase, qui permet à son tour l'inhibition de l'activité ostéoclastique, avec l'augmentation consécutive de la densité minérale osseuse. The present invention relates to pharmaceutical, nutraceutical, dietetic and nutritional compositions for the treatment of postmenopausal syndrome, containing: a) soy saponins; b) soy isoflavones; c) vitamin K. Post-menopausal syndrome, characterized by hot flashes, sweating, headache, nervousness, depression, and osteoporosis, has long been treated with hormone replacement therapy with estrogens, the risks of which are, however, well known Indeed the administration of estrogens, especially during a long period, can favor the appearance of tumors caused by these. An alternative to the replacement therapy with estrogens is that which uses soy isoflavones, of which I ' activity similar to that of estrogens is abundantly documented in the literature This activity similar to that of estrogens proves to be extremely useful in the treatment of post-menopausal syndrome, because not only does it cause a reduction in symptoms such as hot flushes, nervousness, headache, palpitations, but it also helps fight problems related to osteoporosis, thanks to its inhibitory action on tyrosine kinase, which in turn allows the inhibition of osteoclastic activity, with the consequent increase in bone mineral density.
L'action de réduction et de lutte contre la prolifération du cholestérol des saponines de soja est bien connue dans la littérature. The action of reducing and combating the proliferation of cholesterol from soy saponins is well known in the literature.
N Binkley et al (Am J Clin Nutr 200; 72: 1523-8) a divulgué qu'un 25 apport insuffisant en vitamine K dans le régime alimentaire contribue au développement d'ostéoporoses, et qu'une intégration en vitamine K réduit la concentration plasmatique d'ostéocalcine. N Binkley et al (Am J Clin Nutr 200; 72: 1523-8) disclosed that insufficient intake of vitamin K in the diet contributes to the development of osteoporosis, and that integration of vitamin K reduces the concentration osteocalcin plasma.
WO 02074308 décrit des compositions utiles pour la prévention de l'ostéoporose, contenant, entre autres, des isoflavones de soja et de la vitamine 30 K. On a à présent découvert que l'association de saponines de soja, d'isoflavones de soja et de vitamine K est particulièrement efficace dans le traitement du syndrome post-ménopausique Plus particulièrement, cette association permet d'obtenir une disparition presque totale des bouffées de 35 chaleur et une prévention très efficace de l'ostéoporose. WO 02074308 describes compositions useful for the prevention of osteoporosis, containing, among other things, soy isoflavones and vitamin 30 K. It has now been discovered that the combination of soy saponins, soy isoflavones and of vitamin K is particularly effective in the treatment of post-menopausal syndrome More particularly, this combination makes it possible to obtain an almost total disappearance of hot flashes and a very effective prevention of osteoporosis.
C'est donc pourquoi la présente invention a pour objet des compositions pharmaceutiques, nutraceutiques, diététiques, nutritionnelles contenant des saponines de soja, des isoflavones de soja et de la vitamine K, pour le traitement du syndrome post-ménopausique. This is why the present invention relates to pharmaceutical, nutraceutical, dietetic and nutritional compositions containing soy saponins, soy isoflavones and vitamin K, for the treatment of post-menopausal syndrome.
Les compositions de la présente invention montrent un effet supérieur à celui obtenu par la somme des effets obtenus suite à l'administration séparée de 5 chacun des éléments de 1 ' association Cet effet supérieur est apparemment d à une synergie entre saponines/isoflavones et vitamine K, qui permet d'obtenir une réponse plus rapide et plus efficace. The compositions of the present invention show an effect greater than that obtained by the sum of the effects obtained following the separate administration of each of the elements of the association. This superior effect is apparently due to a synergy between saponins / isoflavones and vitamin K , which provides a faster and more efficient response.
De préférence, les saponines de soja et les isoflavones de soja proviennent toutes les deux d'un seul extrait de soja, caractérisé par un titre 10 défini en saponines et en isoflavones D'après l'invention, cet extrait de soja contiendra de préférence d'environ 50 à environ 200 mg de saponines et d' environ 40 à environ 150 mg d'isoflavones. Preferably, the soy saponins and the soy isoflavones both come from a single soy extract, characterized by a defined titer of saponins and isoflavones. According to the invention, this soy extract will preferably contain '' about 50 to about 200 mg of saponins and about 40 to about 150 mg of isoflavones.
La teneur en vitamine K dans les compositions de l'invention variera d'environ 0,5 à environ 250 mcg, de préférence entre 50 et 150 mcg. The content of vitamin K in the compositions of the invention will vary from about 0.5 to about 250 mcg, preferably between 50 and 150 mcg.
Les compositions de la présente invention pourront être formulées de manière appropriée pour l'administration par voie orale et seront préparées selon les méthodes conventionnelles bien connues dans le secteur de la technique pharmaceutique, comme celles décrites dans "Remington's Pharmaceutical Handbook", Mack Publishing Co, N Y, USA, en utilisant des excipients, 20 diluants, agents de charge, anti- agglomérants acceptables pour leur emploi final. On reporte ci après un exemple de formulation de l'invention. The compositions of the present invention may be formulated appropriately for oral administration and will be prepared according to conventional methods well known in the pharmaceutical industry, such as those described in "Remington's Pharmaceutical Handbook", Mack Publishing Co, NY, USA, using excipients, diluents, bulking agents, anti-caking agents acceptable for their end use. An example of formulation of the invention is given below.
Exemple Comprimés de 900 mg Ingrédient Quantité Extrait de soja titré en: 533 mg 26 % de saponines (correspondant à 141,24 mg) % d'isoflavones (correspondant à 80 mg) Vitamine K 1 100 mcg Cellulose microcristalline 135,267 Phosphate de calcium 100,000 Amidon de mas 80,000 Polyvinylpyrrolidone 25,000 Bioxyde de silicium 15,000 Stéarate de magnésium 9,000 Example 900 mg tablets Ingredient Quantity Soy extract titrated in: 533 mg 26% saponins (corresponding to 141.24 mg)% isoflavones (corresponding to 80 mg) Vitamin K 1 100 mcg Microcrystalline cellulose 135.267 Calcium phosphate 100,000 Starch of mas 80,000 Polyvinylpyrrolidone 25,000 Silicon dioxide 15,000 Magnesium stearate 9,000
Claims (3)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002723A ITMI20022723A1 (en) | 2002-12-20 | 2002-12-20 | COMPOSITIONS FOR THE TREATMENT OF POST-MENOPAUSE SYNDROME. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2848853A1 true FR2848853A1 (en) | 2004-06-25 |
Family
ID=32448926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0304213A Pending FR2848853A1 (en) | 2002-12-20 | 2003-04-04 | Treatment of post-menopausal syndrome, using pharmaceutical or dietetic compositions containing synergistic combination of soya isoflavones, soya saponins and vitamin K |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2848853A1 (en) |
| IT (1) | ITMI20022723A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007021166A1 (en) * | 2005-08-12 | 2007-02-22 | World-Trade Import-Export, Wtie, A.G. | Isoflavone composition for the treatment of menopausal physiological disorders and symptoms |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19732866A1 (en) * | 1997-07-30 | 1999-02-18 | Indena Spa | Soya extract containing group B soya saponin(s) |
| EP0906761A2 (en) * | 1997-10-02 | 1999-04-07 | Archer-Daniels-Midland Company | Method of preparing and using phytochemicals |
| US6280777B1 (en) * | 1997-07-30 | 2001-08-28 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
| WO2002074308A1 (en) * | 2001-03-15 | 2002-09-26 | Roche Vitamins Ag | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| EP1321149A1 (en) * | 2001-12-18 | 2003-06-25 | Marfarma S.R.L. | Compositions for relieving symptoms of menopausal syndrome |
-
2002
- 2002-12-20 IT IT002723A patent/ITMI20022723A1/en unknown
-
2003
- 2003-04-04 FR FR0304213A patent/FR2848853A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19732866A1 (en) * | 1997-07-30 | 1999-02-18 | Indena Spa | Soya extract containing group B soya saponin(s) |
| US6280777B1 (en) * | 1997-07-30 | 2001-08-28 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
| EP0906761A2 (en) * | 1997-10-02 | 1999-04-07 | Archer-Daniels-Midland Company | Method of preparing and using phytochemicals |
| WO2002074308A1 (en) * | 2001-03-15 | 2002-09-26 | Roche Vitamins Ag | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| EP1321149A1 (en) * | 2001-12-18 | 2003-06-25 | Marfarma S.R.L. | Compositions for relieving symptoms of menopausal syndrome |
Non-Patent Citations (4)
| Title |
|---|
| HIDAKA TAKAO ET AL: "Treatment for patients with postmenopausal osteoporosis who have been placed on HRT and show a decrease in bone mineral density: effects of concomitant administration of vitamin K(2).", JOURNAL OF BONE AND MINERAL METABOLISM. 2002, vol. 20, no. 4, 2002, pages 235 - 239, XP001206344, ISSN: 0914-8779 * |
| SCAMBIA G ET AL: "Clinical effects of a standardized soy extract in postmenopausal women: A pilot study", MENOPAUSE 2000 UNITED STATES, vol. 7, no. 2, 2000, pages 105 - 111, XP009048138, ISSN: 1072-3714 * |
| THIEDKE C C: "Menopause", CLINICS IN FAMILY PRACTICE 2002 UNITED STATES, vol. 4, no. 4, 2002, pages 985 - 1003, XP009048144, ISSN: 1522-5720 * |
| YAMAGUCHI M ET AL: "Effect of vitamin K2 (menaquinone-7) in fermented soybean (natto) on bone loss in ovariectomized rats.", JOURNAL OF BONE AND MINERAL METABOLISM. 1999, vol. 17, no. 1, 1999, pages 23 - 29, XP001205787, ISSN: 0914-8779 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007021166A1 (en) * | 2005-08-12 | 2007-02-22 | World-Trade Import-Export, Wtie, A.G. | Isoflavone composition for the treatment of menopausal physiological disorders and symptoms |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20022723A1 (en) | 2004-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1172080B1 (en) | Use of a composition comprising vitamins and mineral salts to reduce the hairloss and/or to promote the hairregrowth | |
| ZA200604097B (en) | Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences | |
| van Praag et al. | 5-hydroxytryptophan in combination with clomipramine in “therapy-resistant” depressions | |
| ES2247264T3 (en) | PHARMACEUTICAL COMPOSITION | |
| Kähönen et al. | Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment | |
| KR20120046795A (en) | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same | |
| FR2698268A1 (en) | Oral compsns. for protecting skin against ultraviolet radiation - contg. amino acids, copper salt, carotene and vitamins. | |
| FR2848853A1 (en) | Treatment of post-menopausal syndrome, using pharmaceutical or dietetic compositions containing synergistic combination of soya isoflavones, soya saponins and vitamin K | |
| CN1822848A (en) | Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions | |
| JP2007517785A (en) | Composition comprising an aqueous extract of red grape leaves and a diuretic for the treatment of chronic venous insufficiency | |
| FR2710267A1 (en) | Composition for the treatment of male impotence | |
| US20050142235A1 (en) | Composition comprising an aqueous extract of red vine leaves and an antithrombotic agent | |
| WO2012063198A1 (en) | Compositions for the prevention and treatment of erectile dysfunction and impotence and for improving sport performance | |
| DK1638417T3 (en) | COMBINATIONS OF VASO PROTECTIVE AGENTS AND FORMS CONTAINING THESE | |
| FR2936711A1 (en) | Composition, useful as a dietary supplement for e.g. the prevention and/or treatment of hypercholesterolemia, comprises a combination of hypolipidemic agents including at least one dry extract of artichoke leaves and red yeast rice | |
| US20060193923A1 (en) | Compositions and methods for increasing muscle mass and strength, improving athletic performance, and/or reducing body fat mass leading to weight loss | |
| BE1026496B1 (en) | Compound and composition for use in the treatment of premenstrual syndrome and / or premenstrual dysphoric disorder | |
| FR2898059A1 (en) | Phytohormonal composition useful to prevent and fight against (pre)menopausal disorders e.g. hot flashes, night sweats, fatigability and mood and sleep disorders, comprises combination of herbal extracts rich in lignans and sage extract | |
| Praag et al. | 5-Hydroxytryptophan in combination with clomipramine in “therapy-resistant” depressions | |
| EP1433388A1 (en) | Algae-based food supplement | |
| Preston et al. | P-241 MP-30: Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the respond study | |
| US20050171030A1 (en) | Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins | |
| FR2770976A1 (en) | Plant-based food supplement contains Dioscorea extract | |
| EP3738596B1 (en) | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder | |
| AU702894B2 (en) | Therapeutic compositions |